Peptides and SARMs on TikTok: sorting hype from actual evidence

What did @nemanjamilovic actually say?

Honestly, this is a difficult video to fact-check in the traditional sense. The transcript provided is nearly incoherent, a fragmented string of phrases that appear to be either a transcription error, auto-caption garbling of a non-English language, or a technical artifact. The caption is in Serbian and warns followers to "be careful with these things" (peptides and SARMs), noting there is "not much science yet" and that he sees them being used massively. That caption sentiment, at least, is worth examining seriously.

The core message appears to be a general caution about peptides and SARMs, framed as an educational warning rather than a promotion. If that is what was actually communicated in the video, it is a more responsible stance than most content in this category. But we cannot verify specific claims from the audio transcript as rendered, so we are grading what we can actually read.

Does the science back this up?

The caption claim that there is "not much science yet" on peptides and SARMs is broadly accurate, and the research base depends heavily on which compound you are talking about. BPC-157, for example, has a reasonable body of animal data showing accelerated tendon and gut tissue repair, but human randomized controlled trials are essentially absent as of 2024. TB-500 (thymosin beta-4) is in a similar position. SARMs like ostarine and ligandrol have a handful of phase II human trials, mostly in muscle-wasting disease populations, but long-term safety data is missing.

A 2022 review by Bhasin et al. in the New England Journal of Medicine noted that SARMs show anabolic effects in early trials but that "long-term cardiovascular, hepatic, and endocrine risks remain poorly characterized." That is a polite way of saying we do not know what happens when a healthy 25-year-old takes these for two years. The warning in the caption is not fearmongering. It reflects the actual state of the evidence.

What did they get wrong (or right)?

On the caption content alone, the creator largely got it right. Saying these substances are being used "massively" without adequate scientific backing is accurate. Peptides and SARMs are widely available through gray-market sources, research chemical vendors, and compounding pharmacies operating in legal gray zones. Many users are self-dosing compounds that have never cleared a phase III human trial.

What the video does not appear to address, based on the caption alone, is the specific risks tied to specific compounds. MK-677, for instance, is not technically a SARM but is frequently grouped with them. It increases IGF-1 and can cause significant water retention, insulin resistance, and potentially elevate cancer risk in susceptible individuals. GHK-Cu has a comparatively benign safety profile in topical form but is far less studied systemically. Lumping all peptides and SARMs into one category without distinguishing risk profiles is an oversimplification, even if the general caution is warranted.

What should you actually know?

If you are considering any peptide or SARM, the evidence gaps are real and they matter. Here is what the actual research tells us, without the hype.

• BPC-157 has shown accelerated healing in rodent models across multiple studies, including work by Sikiric et al. published repeatedly in Current Pharmaceutical Design, but zero completed randomized human trials exist as of this writing.
• Ostarine (MK-2866) demonstrated lean mass gains in phase II trials (Dalton et al., 2011, Journal of Cachexia, Sarcopenia and Muscle) but caused dose-dependent testosterone suppression even at low doses, which is the opposite of what most recreational users expect.
• SARMs purchased outside of clinical trials are frequently mislabeled. A 2017 JAMA study by Van Wagoner et al. found that 52% of products marketed as SARMs contained unapproved drugs, wrong doses, or no active ingredient at all.
• No peptide or SARM has regulatory approval for use in healthy adults for performance or longevity purposes in the US or EU as of 2024.

A physician consultation, ideally with someone who actually understands the literature rather than just repeating manufacturer claims, is the minimum bar before touching any of these compounds.

Bottom line on this video

The creator's instinct to pump the brakes on mass peptide and SARM use is correct. The specific science behind that caution is solid. The execution, based on what we can evaluate, is vague enough that viewers probably do not come away knowing which compounds carry which risks or why the regulatory gap exists. A good warning is not the same as useful education, and this video appears to be closer to the former.